Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
2d agoen
From the article
Conditions : Schizophrenia Interventions : Drug: Xanomeline/Trospium Chloride; Drug: Placebo Sponsors : Karuna Therapeutics, Inc., a Bristol Myers Squibb company Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Northwestern study identifies schizophrenia biomarker and potential drug candidate for cognitive symptoms
A Northwestern University study in humans and mice has identified a novel biomarker for schizophrenia that could also serve as a drug candid
news.northwestern.edu·3mo agoGSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
GSK·17y ago
Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData
globaldata.com·5d ago
Pharmaceutical LSD (MM120) Shows Promise in Treating Generalized Anxiety Disorder in UCSF Clinical Trials
Researchers at UCSF are testing MM120, a pharmaceutical form of LSD, as a treatment for generalized anxiety disorder (GAD). The treatment ha
sciencedaily.com·3mo ago
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK·17y ago
Anixa Biosciences Aktie: Höchste Lira-cel-Dosis erreicht
aktiencheck.de
Comments
Sign in to join the conversation.
No comments yet. Be the first.